17285-36-8

Usage

Uses

Used in Pharmaceutical Synthesis:
5,6-Dichloropyridazin-3(2H)-one is used as a key intermediate in the synthesis of various pharmaceuticals for its potential to contribute to the development of new drugs with antimicrobial, antiparasitic, and antiviral properties.
Used in Agrochemical Synthesis:
In the agrochemical industry, 5,6-Dichloropyridazin-3(2H)-one is utilized as a building block for the creation of compounds that can help protect crops from pests and diseases, leveraging its antimicrobial and antiparasitic capabilities.
Used in Material Science:
5,6-Dichloropyridazin-3(2H)-one is employed in material science for its potential to enhance or create new materials with specific properties, such as improved stability or reactivity, due to its unique chemical structure.
Used as a Reagent in Organic Synthesis:
As a reagent, 5,6-Dichloropyridazin-3(2H)-one is used in organic synthesis to facilitate specific chemical reactions, contributing to the formation of desired products in a controlled manner.
Each of these applications takes advantage of the compound's unique properties, highlighting its importance and versatility in scientific research and industrial applications.

InChI:InChI=1/C4H2Cl2N2O/c5-2-1-3(9)7-8-4(2)6/h1H,(H,7,9)

Upstream product

• 6082-66-2 3,4,6-trichloropyridazine 
• 64-19-7 acetic acid 

Downstream Products

• 17285-22-2 5-amino-6-chloro-3(2H)-pyridazinone 
• 112342-59-3 3,4-dichloro-6-methoxypyridazine 
• 6794-35-0 5,6-dichloro-2-methylpyridazin-3-(2H)-one 
• 1051923-57-9 5,6-dichloro-2-(phenylmethyl)-3(2H)-pyridazinone 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS

The invention relates to a compound of Formula I, pharmaceutical compositions comprising a compound of Formula I, and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I to

PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER

The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

BROMODOMAIN INHIBITORS

The present invention provides for compounds of formula (I) wherein Rx, X, Y, Y1, L1, A1, A2, A3, A4, A5, A6, A7, and A8, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

PYRIDINONE AND PYRIDAZINONE DERIVATIVES

Compounds of formula (I) wherein A1, A2, A3, A4, J, L, G, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS are disclosed. Pharmaceutical compositions comprising one or more compounds of formula (I) also are disclosed.

Pyridinone and Pyridazinone Derivatives

The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, J, and X3 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereo